Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Pharmacy chain BENU is warning that a steep price increase for the blood thinner Eliquis is threatening patient access to ...

Eight New Jersey-based companies have earned spots on U.S. News & World Report’s 2024 list of “Best Companies to Work For." ...

Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...